drugset / Trial / NCT01603277

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

NCT01603277

Phase 2 Completed 160 enrolled Humanigen, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.

Timeline

Start
2012-07
Primary completion
2013-07
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenzilumab Monoclonal antibody 400 mg Intravenous

Indications